Anvisa approves new treatment for advanced cancer in Brazil

Anvisa (National Health Surveillance Agency) approved TECARTUS® (brexucabtagene autoleucel), a gene therapy drug developed by the Kite laboratory, to treat hematologic cancer.

Indicated for adults, TECARTUS® is the first therapeutic advance for this rare type of cancer in the country. Read more here

ELS can help you throughout the process, from drug development to final registration in Brazil, as well as in the rest of Latin America and Europe.

Please do not hesitate to contact your local ELS consultant or via email

Contact us

We will contact you as soon as possible.